Nucleoside derivatives as inhibitors of RNA-dependent RNA...

Details Nucleoside derivatives as inhibitors of RNA-dependent RNA... Nucleoside derivatives as inhibitors of RNA-dependent RNA...

2007-04-10

2007-04-10

Jiang, S. Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S027130, C536S027200

Reexamination Certificate

active

11496338

ABSTRACT:
The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.

REFERENCES:
patent: 3480613 (1969-11-01), Walton
patent: 6348587 (2002-02-01), Schinazi et al.
patent: 6777395 (2004-08-01), Bhat et al.
patent: 2002/0019363 (2002-02-01), Ismaili et al.
patent: 2002/0055483 (2002-05-01), Watanabe et al.
patent: 2002/0198171 (2002-12-01), Schinazi et al.
patent: 2003/0050229 (2003-03-01), Sommadossi et al.
patent: 2003/0060400 (2003-03-01), LaColla et al.
patent: 1.581.628 (1969-09-01), None
patent: 1209 654 (1970-10-01), None
patent: WO 93/18051 (1993-09-01), None
patent: WO 99/43691 (1999-09-01), None
patent: WO 01/32153 (2001-05-01), None
patent: WO 01/60315 (2001-08-01), None
patent: WO 01/79246 (2001-10-01), None
patent: WO 01/90121 (2001-11-01), None
patent: WO 01/92282 (2001-12-01), None
patent: WO 02/18404 (2002-03-01), None
patent: WO 02/32920 (2002-04-01), None
patent: WO 02/048165 (2002-06-01), None
patent: WO 02/048165 (2002-06-01), None
patent: WO 02/069903 (2002-09-01), None
patent: WO 02/069903 (2002-09-01), None
patent: WO 02/094289 (2002-11-01), None
patent: WO 02/100354 (2002-12-01), None
patent: WO 02/100354 (2002-12-01), None
patent: WO 02/100415 (2002-12-01), None
patent: WO 03/000200 (2003-01-01), None
patent: WO 03/000713 (2003-01-01), None
patent: WO 03/015798 (2003-02-01), None
patent: WO 03/026589 (2003-04-01), None
patent: WO 03/026675 (2003-04-01), None
patent: WO 03/051881 (2003-06-01), None
patent: WO 03/051896 (2003-06-01), None
patent: WO 03/051897 (2003-06-01), None
patent: WO 03/051898 (2003-06-01), None
patent: WO 03/051899 (2003-06-01), None
patent: WO 03/062255 (2003-07-01), None
patent: WO 03/093290 (2003-11-01), None
Ono et al., “Oligodeoxynucleotides Containing : . . . Endonucleases,” Eleventh Symposium on Nucleic Acids Chemistry, Tokyo, Japan, Nov. 1-2, 1983, pub. Nucleic Acids Symp. Series, # 12, A. E. Pritchard (ed.), IRL Pr., Washington, DC, 1983, pp. 67-70 only.
Chu et al., “9-Deaazadenosine—A New Potent Antitumor Agent,” Biochemical Pharmacology, 33(8), 1229-1234 (1984).
Seela et al., “7-(§-D-Arabinofuranosyl)-2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidin—Synthese, Selectiver Halogensaustausch und Einfluss Glyconischer Schutzgruppen auf die . . . ,” Liebigs Annalen der Chemie, 1984(4), 722-733 (Apr. 1984).
Yukino et al., “Mouse Hepatitis Virus. II . . . ,” Virus (Osaka), 8, 67-72 (1958); Chemical Abstracts, 52(18), Abstr. No. 15721d-f (Sep. 25, 1958) & HCAPlus printout of document No. 52:89150; only abstracts supplied.
Flockhart et al., “ATP Analog Specificity of cAMP-Dependent Protein Kinase, cGMP-Dependent Protein Kinase, and Phosphorylase Kinase,” European Journal of Biochemistry, 140(2), 289-295 (Apr. 16, 1984).
Gupta et al., “Genetic and Biochemical Studies on Mutants of CHO Cells Resistant to 7-Deazapurine Nucleosides: Differences in the Mechanisms of Action of Toyocamycin and Tubercidin,” Biochemical & Biophysical Res. Comm., 120(1), 88-95 (Apr. 16, 1984).
Beers et al. (eds.), The Merck Manual of Diagnosis and Therapy, 17th Edition, Merck 7 Co., Whitehouse Station, New Jersey, Jun. 1999, only pp. 377-386, 1132 and 1280 supplied.
Walton, E. et al., “Branched-Chain Sugar Nucleosides. V. Synthesis and Antiviral Properties of Several Branched-Chain Sugar Nucleosides”, J. Med. Chem., vol. 12, pp. 306-309 (1969).
Matsuda, A. et al., “Radical Deoxygenation of Tert-Alcohols In 2′-Branched-Chain Sugar Pyrimidine Nucleosides: Synthesis and Antileukemic Activity of 2′ -Deoxy-2′ (S)-Methylcytidine”, Chem. Pharm. Bull., vol. 35, pp. 3967-3970 (1987).
Matsuda, A. et al., Alkyl Addition Reaction of Pyrimidine 2′-Ketonucleosides: Synthesis of 2′-Branched-Chain Sugar Pyrimidine Nucleosides (Nucleosides and Nucleotides. LXXXI), Chem. Pharm. Bull., vol. 36, pp. 945-953 (1988).
Murai, Y. et al., “A Synthesis and an X-Ray Analysis of 2′-C-, 3′-C- and 5′-C-Methylsangivamycins”, Heterocycles, vol. 33, pp. 391-404 (1992).
Limori, T. et al., “2′-C-, 3′-C- and 5′-C-Methylsangivamycins: Conformational Lock with the Methyl Group”, Tetrahedron Letters, vol. 3, No. 49, pp. 7273-7276 (1991).
Wolfe, M. et al., “A Consise Synthesis of 2′-C-Methylribonucleosides”, Tetrahedron Letters, vol. 36, No. 42, pp. 7611-7614 (1995).
Harry-O'kuru, R. et al., “A Short, Flexible Route toward 2′-C-Branched Ribonucleosides”, J. Org. Chem., vol. 62, pp. 1754-1759 (1997).
Gallo, M. et al., “Synthesis of 2′-Modified Nucleotides”, Molecules, vol. 5, pp. 727-729 (2000).
Beigelman, L. et al., “New Synthesis of 2′-C-Methylnucleosides Starting From D-Glucose and D-Ribose” , Carbohydrate Research, vol. 166, pp. 219-232 (1987).
Anzai, K. et al, “A New Antibiotic, Tubercidin”, The Journal of Antibiotics., vol. X, No. 5, pp. 201-205 (1957).
Tolman, R. et al., “Pyrrolopyrimidine Nucleosides. III. The Total Synthesis of Toyocamycin, Sangivamycin, Tubercidin, and Related Derivatives”, Journal of the American Chemical Society, vol. 91, No. 8, pp. 2102-2108 (1969).
Tolman, R. et al., “Pyrrolo[2,3-d]pyrimidine Nucleoside Antibiotics. Total Synthesis and Structure of Toyacamycin, Unamycin B, Vengicide, Antibiotic E-212, and Sangivamycin (BA-90212)”, Journal of the American Chemical Society, vol. 90, No. 2, pp. 24-526 (1968).
Siddiqi, S. et al., “Search for New Purine- and Ribose-Modified Adenosine Analogues as Selective Agonists and Antagonists at Adenosine Receptors”, J. Med. Chem., vol. 38, pp. 1174-1188 (1995).
Franchetti, P. et al., “2′-C-Methyl Analogues of Selective Adenosine Receptor Agonists: Synthesis and Binding Studies”, J. Med. Chem., vol. 41, pp. 1708-1715 (1988).
Kalinichenko, E. et al, “Substrate Specificity of Adenosine Deminase. Role of Methyl Groups at the 2′-, 3′-, and 5′-Carbon Atoms of Adenosine”, Bioorganicheskaya Khimiya, vol. 14, No. 9, pp. 1157-1161 (1988).
Wolf, et al., “New 2′-C-Branched-Chain Sugar Nucleoside Analogs with Potential Antiviral or Antitumor Activity”, Synthesis, pp. 773-778 (Aug. 1992).

Affiliated with

Also associated with

Rating

Nucleoside derivatives as inhibitors of RNA-dependent RNA... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleoside derivatives as inhibitors of RNA-dependent RNA..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleoside derivatives as inhibitors of RNA-dependent RNA... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3768412